公开(公告)号：WO2023092119A2

公开(公告)日：2023-05-25

申请号：PCT/US2022/080235

申请日：2022-11-21

Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD

Inventor： HARARI, Alexandre ,  DANGAJ, Denarda ,  COUKOS, George

IPC: C12Q1/6886 ,  G01N33/574 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2800/52 ,  G01N33/5743

Abstract: This disclosure describes novel methods for predicting responsiveness of a patient to treatment of a cancer therapy (e.g., adoptive cell therapy (ACT)) and novel CD8+ T-cell network-based biomarkers that can improve patient selection and guide the design of adoptive cell therapy clinical trials.

公开(公告)号：WO2023288203A2

公开(公告)日：2023-01-19

申请号：PCT/US2022/073611

申请日：2022-07-11

Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD

Inventor： COUKOS, George ,  HARARI, Alexandre ,  BOBISSE, Sara ,  ARNAUD, Marion ,  BASSANI-STERNBERG, Michal

IPC: C07K14/725 ,  A61P35/00 ,  C07K14/82 ,  A61K38/17 ,  A61K35/17 ,  A61K38/00 ,  C07K14/7051

Abstract: This disclosure describes novel T cell receptors (TCRs) specific for tumor-associated antigens (TAAs) and methods of use thereof. The disclosed TCRs and methods of use expand the applications of adoptive cell therapy and TCR-based cellular immunotherapies.

公开(公告)号：WO2022229464A1

公开(公告)日：2022-11-03

申请号：PCT/EP2022/061639

申请日：2022-04-29

Applicant: TIGEN PHARMA SA ,  LUDWIG INSTITUTE FOR CANCER RESEARCH LTD ,  CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV)

Inventor： COUKOS, George ,  HARARI, Alexandre ,  STEINER, Simone ,  SALMON, Florence

IPC: C12N5/0783 ,  A61K39/00

Abstract: The present invention relates to a population of lymphocytes comprising at least 90% CD3+ T cells and less than 5% B cells, wherein at least 70% of said T cell portion are viable, at least 20% are CD27/CD28 double positive and less than 10% are triple positive for CD45RA, CD57 and KLRG1 and a method for expansion of a population of lymphocytes specific for one or more antigens comprising a single culture phase.

公开(公告)号：WO2021262671A2

公开(公告)日：2021-12-30

申请号：PCT/US2021/038409

申请日：2021-06-22

Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD

Inventor： REN, Bing ,  ZHU, Chenxu

IPC: C12Q1/6806 ,  C12Q1/6869 ,  G16B5/00 ,  C12Q1/6853

Abstract: The present invention relates to methods for the joint analysis of regulation of gene expression and gene expression in single cells. Provided are methods for obtaining gene expression information for a single nucleus, the methods comprising deriving a DNA library from the genomic DNA in one or more nuclei and deriving an RNA library from the RNA in one or more nuclei, sequencing the molecules in the RNA library and the DNA library, and correlating the RNA library and the DNA library for each of the one or more nuclei.

公开(公告)号：WO2020243455A1

公开(公告)日：2020-12-03

申请号：PCT/US2020/035157

申请日：2020-05-29

Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD ,  CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS ,  UNIVERSITE DE LAUSANNE

Inventor： DUNN, Steven, M. ,  FIERLE, Julie, K. ,  COUKOS, George

IPC: A61K39/00 ,  A61K39/395 ,  C12P21/08 ,  C07K16/00 ,  C12N5/16 ,  C12N15/00 ,  C07H21/04

Abstract: Provided herein are antibodies and antigen-binding portions thereof that bind to tumor endothelial marker 1 (TEM1), as well as methods of using the disclosed antibodies and antigen-binding portions thereof, including methods of treating cancer, reducing tumor growth, reducing tumor metastasis, and/or reducing tumor-associated fibrosis in a subject in need thereof.

公开(公告)号：WO2019136413A4

公开(公告)日：2019-07-11

申请号：PCT/US2019/012627

申请日：2019-01-08

Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD

Inventor： SONG, Chunxiao ,  LIU, Yibin

IPC: C12N9/02 ,  C12P19/18 ,  C12Q1/26 ,  C12Q1/6806 ,  C12Q1/6827 ,  C12Q1/6869

Abstract: This disclosure provides methods for bisulfite-free identification in a nucleic acid sequence of the locations of 5-methylcytosine, 5- hydroxymethylcytosine, 5-carboxylcytosine and 5- formylcytosine.

公开(公告)号：WO2017096189A1

公开(公告)日：2017-06-08

申请号：PCT/US2016/064657

申请日：2016-12-02

Applicant: AGENUS INC. ,  MEMORIAL SLOAN-KETTERING CANCER CENTER ,  LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.

Inventor： WILSON, Nicholas S. ,  WAIGHT, Jeremy D. ,  RITTER, Gerd ,  TSUJI, Takemasa ,  LEGER, Olivier ,  SEIBERT, Volker ,  SCHAER, David ,  MERGHOUB, Taha ,  UNDERWOOD, Dennis J. ,  GONZALEZ, Ana M. ,  VAN DIJK, Marc

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/30

CPC classification number: C07K16/2878 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/76

Abstract: The present disclosure provides antibodies that specifically bind to human GITR, as well as compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and deactivate, reduce, or inhibit GITR activity. The present disclosure also provides methods for treating autoimmune or inflammatory diseases disorders, by administering an antibody that specifically binds to human GITR and deactivates, reduces, or inhibits GITR activity.

Abstract translation: 本公开提供了特异性结合人GITR的抗体，以及包含这种抗体的组合物。 在具体方面，抗体特异性结合人GITR并使GITR活性失活，减少或抑制。 本公开内容还提供了通过施用特异性结合人GITR并失活，降低或抑制GITR活性的抗体来治疗自身免疫疾病或炎症疾病的方法。

公开(公告)号：WO2016201282A2

公开(公告)日：2016-12-15

申请号：PCT/US2016/036965

申请日：2016-06-10

Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD

Inventor： VAN SNICK, Jacques ,  UYTTENHOVE, Catherine

IPC: A61K39/395 ,  C07K16/30

CPC classification number: C07K16/22 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6845 ,  A61K2039/505 ,  A61K2039/54 ,  A61P35/00 ,  A61P35/04 ,  C07K16/30 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/76 ,  G01N33/57488 ,  G01N2333/495

Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-β3) are provided, particularly recognizing human and mouse TGF-β3, particularly antibodies and fragments that do not recognize or bind TGF-β1 or TGF-β2. Particular antibodies are provided which specifically recognize and neutralize TGF-β3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody MTGF-β3-9, MTGF-β3-12, MTGF-β3-16, MTGF-β3-17 and MTGF-β3-19, whose sequences are provided herein.

Abstract translation: 提供了结合转化生长因子β3（TGF-β3）的特异性结合成员，特别是其抗体及其片段，特别是识别人和小鼠TGF-β3，特别是不识别或结合TGF-β1或TGFβ的抗体和片段 -β2。 提供特异性识别和中和TGF-β3的特异性抗体。 这些抗体可用于诊断和治疗与活化或升高的TGF-β3（包括癌症）相关的病症，以及用于调节免疫细胞和免疫应答，包括对癌症或癌症抗原的免疫应答。 抗TGF-β3抗体，其可变区或CDR结构域序列及其片段也可用于与化学治疗剂，免疫调节剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。 这种抗体以本发明的抗体为例，包括本文提供的序列的抗体MTGF-β3-9，MTGF-β3-12，MTGF-β3-16，MTGF-β3-17和MTGF-β3-19。

公开(公告)号：WO2016196237A1

公开(公告)日：2016-12-08

申请号：PCT/US2016/034508

申请日：2016-05-27

Applicant: AGENUS INC. ,  LUDWIG INSTITUTE FOR CANCER RESEARCH LTD ,  MEMORIAL SLOAN KETTERING CANCER CENTER

Inventor： DIJK, Marc, Van ,  MUNDT, Cornelia, Anne ,  RITTER, Gerd ,  SCHAER, David ,  WOLCHOK, Jedd, David ,  MERGHOUB, Taha ,  SAVITSKY, David, Adam ,  FINDEIS, Mark, Arthur ,  WILSON, Nicholas, Stuart

IPC: C07K16/28

CPC classification number: C07K16/2818 ,  A61K47/6803 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/505 ,  C07K16/283 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Abstract translation: 本公开提供特异性结合人CTLA-4并拮抗CTLA-4功能的抗体。 还提供了包含这些抗体的药物组合物，编码这些抗体的核酸，用于制备这些抗体的表达载体和宿主细胞，以及使用这些抗体治疗受试者的方法。

公开(公告)号：WO2015117199A1

公开(公告)日：2015-08-13

申请号：PCT/AU2015/050036

申请日：2015-02-04

Applicant: MONASH UNIVERSITY ,  MEMORIAL SLOAN-KETTERING CANCER CENTRE ,  LUDWIG INSTITUTE FOR CANCER RESEARCH LTD

Inventor： LACKMANN, Martin ,  JANES, Peter W. ,  MUDIYANSELAGE, Lakmali Atapattu ,  SCOTT, Andrew M. ,  NIKOLOV, Dimitar B. ,  SAHA, Nayanendu

IPC: G01N33/53 ,  C07K16/28 ,  C07K16/40

CPC classification number: C07K16/40 ,  A61K31/4745 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3038 ,  C07K16/3053 ,  C07K16/3069 ,  C07K2299/00 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/76 ,  C12Y302/00 ,  G01N33/573 ,  G01N33/574 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2333/96486 ,  A61K2300/00

Abstract: Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight AD AMI 0 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.

Abstract translation: 蛋白水解活性高分子量ADAM蛋白酶的表达在肿瘤细胞中相对增加，肿瘤细胞也表达推定的肿瘤干细胞标志物CD133。 抗体或抗体片段如8C7单克隆抗体可用于选择性结合蛋白水解活性的高分子量AD AMI 0蛋白酶，从而检测肿瘤细胞，并且还可用作治疗癌症，肿瘤和其它恶性肿瘤（包括白血病）的治疗剂， 淋巴瘤，肺癌，结肠癌，腺瘤，神经母细胞瘤，脑肿瘤，肾肿瘤，前列腺癌，肉瘤和/或黑素瘤。